Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30439099 | 1.00 | CHEK1 (0.50) | CHEK1CYP11B1CYP11B2CYP19A1TLR7 | |
| SCHEMBL29253937 | 0.86 | PDK2 (0.45) | CHEK1CYP11B1CYP11B2TLR7ABL1 | |
| SCHEMBL25258053 | 0.83 | CHEK1 (0.59) | CHEK1 | |
| SCHEMBL4905901 | 0.81 | TDP1 (0.62) | CHEK1CYP11B1CYP11B2CYP19A1SLC2A1 | |
| SCHEMBL29488899 | 0.77 | CHEK1 (0.51) | CHEK1CYP11B1CYP11B2CYP19A1MAP2K4 | |
| SCHEMBL24369137 | 0.77 | CHEK1 (0.51) | CHEK1CYP11B1CYP11B2CYP19A1MAP2K4 | |
| SCHEMBL24369756 | 0.77 | CTPS1 (0.49) | CHEK1CYP11B1CYP11B2CYP19A1HPGD | |
| SCHEMBL25218243 | 0.76 | ULK1 (0.40) | CHEK1TLR7FYNMAPTPIK3CG | |
| SCHEMBL30438769 | 0.76 | ULK1 (0.40) | CHEK1TLR7FYNMAPTPIK3CG | |
| Trifluoroacetic Acid SCHEMBL30438329 | 0.75 | MKNK1 (0.48) | CHEK1CYP11B2RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122167-A1 | Pyrazine Compounds Useful in the Treatment of Parasitic Protozoal Infection | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| EP-4436960-A1 | PYRAZINE COMPOUNDS USEFUL IN THE TREATMENT OF PARASITIC PROTOZOAL INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| CN-118355005-A | Pyrazine compounds for the treatment of parasitic protozoal infections | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-07-16 | — | — | CN | disclosed |
| WO-2023094305-A1 | PYRAZINE COMPOUNDS USEFUL IN THE TREATMENT OF PARASITIC PROTOZOAL INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023094305-A1 | PYRAZINE COMPOUNDS USEFUL IN THE TREATMENT OF PARASITIC PROTOZOAL INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122167-A1 | Pyrazine Compounds Useful in the Treatment of Parasitic Protozoal Infection | CYP3A5, CYP3A43, CYP51A1 | CHEK1 4827/4885CYP11B1 24/4885CYP11B2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.